Search
Rocket Pharmaceuticals Inc
RCKTAdd to Watchlist
2.560USD
-0.030-1.16%
Close 10-02 16:00（ET）
279.53MMarket Cap
LossP/E TTM
Pre-market 08:27 (ET)2.590USD+0.030+1.17%
Pre-market 08:27 (ET)Rocket Pharmaceuticals Inc (RCKT) Stock Price Target & Forecast
Analyst Rating
Based on 14 analysts giving stock ratings to Rocket Pharmaceuticals Inc in the past month.
Buy
2 Strong Buy
4 Buy
6 Hold
2 Sell
0 Strong Sell
Target Price
8.854USD+245.87%
RCKT Analyst Recommendation Trends
In the current month, RCKT has received 4 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. RCKT average Analyst price target in the last month is 8.854.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2
2
2
2
2
3
3
3
4
4
4
4
4
4
4
4
6
6
6
6
6
6
6
6
0
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
14
14
14
14
14
15
15
15
RCKT Analyst Rating for Peer Comparison
Updated: Oct 4, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
12
6
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, RCKT EPS is projected to reach -0.404 in FY2026Q3, following reported EPS of 1.092 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.45
-0.41
0.24
-0.40
-0.41
Actual
-0.38
-0.42
1.09
--
--
Surprise
+16.07%
-4.31%
+351.53%
--
--
FAQs
What is Rocket Pharmaceuticals Inc's expected revenue for the next quarter?
Rocket Pharmaceuticals Inc's expected revenue is 450.00K.
What is Rocket Pharmaceuticals Inc's price target?
Analysts forecast that Rocket Pharmaceuticals Inc's price target is USD 8.85, with the highest forecast at USD 15.00 and the lowest forecast at USD 3.00.
How have Rocket Pharmaceuticals IncRCKT's recent earnings per share performed?
The market expectation was USD 1.09, while Rocket Pharmaceuticals IncRCKT's earnings per share (EPS) for the previous quarter was USD -0.42. EPS for the next quarter is expected at USD -0.40.
What is the analyst rating for Rocket Pharmaceuticals Inc?
Based on the ratings of Rocket Pharmaceuticals Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.